Clinical TrialJun 25, 2026, 09:26 AM
NeuroSense Reports Positive Biomarker Findings in Alzheimer's Phase 2 Study
AI Summary
NeuroSense Therapeutics Ltd. announced positive biomarker findings from its Phase 2 RoAD proof-of-concept study of PrimeC in Alzheimer’s disease. The study, involving eight participants, showed PrimeC was associated with changes in key AD protein biomarkers like tau and amyloid-beta, as well as other neurodegenerative misfolding proteins. These findings, consistent with PrimeC's mechanism of action and previous ALS results, support continued development and will inform the design of a future, larger clinical study.
Key Highlights
- PrimeC showed positive biomarker findings in Phase 2 RoAD study for Alzheimer's disease.
- Observed changes in hallmark AD protein biomarkers: tau (total), phospho-tau(s), and amyloid-beta 42/40 ratio.
- Distinctive changes in alpha-synuclein and TDP-43, proteins commonly co-occurring with AD.
- Additional changes noted in key biomarkers of oxidative stress and inflammation.
- Findings align with PrimeC's proposed multi-target mechanism of action and ALS program results.
- Study reported a favorable safety and tolerability profile with no serious adverse events.
- Results will inform the design of a future, adequately powered clinical study for PrimeC in AD.
Price Impact
More from NRSN